PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

NICE recommends Tecentriq for first-line NSCLC

The UK National Institute for Health and Care Excellence (NICE) has recommended Roche’s Tecentriq (atezolizumab) monotherapy for untreated metastatic non-small cell lung cancer (NSCLC).
Tecentriq (atezolizumab) is indicated for adults with metastatic NSCLC if their tumours have PD-L1 expression on at least 50% of tumour cells or 10% of tumour-infiltrating immune cells.
The immunotherapy can also only be administered if a patient’s tumours do not have epidermal growth factor receptor (EGFR) or anaplastic lymphoma-infiltrating immune cells.
In the IMpower110 study, Tecentriq was found to improve overall survival for metastatic NSCLC patients compared to chemotherapy – 20.2 months versus 13.1 months, respectively.
In addition, the immunotherapy also improved progression-free survival compared to chemotherapy – 8.1 months compared with 5.0 months.
Although there is no evidence directly comparing Tecentriq with MSD’s Keytruda (pembrolizumab), Roche carried out an indirect comparison, which included data from IMpower110 and two studies comparing Keytruda with chemotherapy – KEYNOTE-024 and KEYNOTE-042.
Results from this indirect comparison suggest that Tecentriq is as effective as Keytruda in delaying disease progression and in extending life, although NICE added that this is uncertain as it is not a direct evidence.
“Despite the uncertainty in the indirect comparison, the most likely cost-effectiveness estimates for [Tecentriq] are within what NICE considers an acceptable use of NHS resources. So [Tecentriq] is recommended,” NICE said in the guidance.
“After working closely with the lung cancer community and NICE, we are now able to offer eligible patients with NSCLC in England, Wales and Northern Ireland a chemotherapy-free treatment option that has been shown to improve overall survival compared to platinum-based chemotherapy alone and which patients can continue to receive until their disease progresses, which can be longer than two years if appropriate,” said Gemma Boni, head of lung cancer, Roche Products Limited.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026